Is prostate cancer more common and more aggressive in African men? Authors
First Online: 17 September 2010 Received: 12 December 2007 Accepted: 13 December 2007 DOI:
Cite this article as: Heyns, C.F. Afr J Urol (2008) 14: 66. doi:10.1007/s12301-008-0007-y Abstract
The highest prostate cancer incidence and mortality rates in the world have been reported among Black African-American men (AAM) living in the United States of America. These rates are significantly higher for AAM compared to White (Caucasian) American men (CAM). However, prostate cancer is not the only malignancy which is more common in AAM compared to White American men or women. Although prostate cancer has the highest Black/White mortality ratio, it is not the only malignancy which has a higher mortality in AAM compared to CAM.
Numerous reports have shown that AAM present with higher grade and stage tumors, higher serum PSA levels, and that they are less likely to receive definitive or curative treatment and have a worse prognosis compared with CAM. It has been suggested that prostate cancer is not only more common, but also more biologically aggressive in AAM compared with CAM. Hypotheses attempting to explain this include genetic differences, dietary factors, higher testosterone levels or increased androgen receptor activity. However, the majority of reports from the USA indicate that, when controlled for major prognostic factors, the outcome for clinically localized as well as advanced prostate cancer does not depend on race. Several studies have indicated that socioeconomic factors, decreased awareness of prostate cancer and limited access or decreased utilization of health care contribute to the poorer outcomes in AAM.
Earlier studies have suggested that prostate cancer is relatively rare among indigenous Black men living in Africa. However, cancer incidence data in Africa are likely to underestimate the true rates because of underdiagnosis and underreporting. The frequency distribution of cancers in African countries, as well as more recent data indicate that prostate cancer is not rare among Black men living in Africa and that the incidence is probably similar to that of White men, although not as high as that reported for Black men living outside Africa. It is well documented that African men with prostate cancer present with more advanced disease and that palliative rather than curative treatment is used in the majority of patients. There are no reliable age-adjusted prostate cancer mortality rates available for African countries. However, there is as yet no evidence that prostate cancer in Black men living inside Africa is biologically more aggressive than in other populations.
Key Words Prostate cancer Africa epidemiology References
Powell IJ, Banerjee M, Bianco FJ, Wood DP, Jr, Dey J, Lai Z, et al. The effect of race/ethnicity on prostate cancer treatment outcome is conditional: A review of Wayne State University data. J.Urol. 2004; Apr;171(4):1508–1512.
Klein EA. Racing for a cure. J. Urol. 2004; Nov;172(5 Pt 1):1773.
Heyns CF, Lecuona AT, Trollip GS. Prostate cancer: Prevalence and treatment in African men. The Journal of Men’s Health & Gender. 2005; Dec;2(4):400–405.
Gronberg H. Prostate cancer epidemiology. Lancet. 2003; Mar 8;361(9360):859–864.
Morton RA,Jr. Racial differences in adenocarcinoma of the prostate in North American men. Urology. 1994; Nov;44(5):637–645.
Fowler JE, Jr, Terrell F. Survival in blacks and whites after treatment for localized prostate cancer. J.Urol. 1996; Jul;156(1):133–136.
Crawford ED. Epidemiology of prostate cancer. Urology. 2003; Dec 22;62(6 Suppl 1):3–12.
Gueye SM, Zeigler Johnson CM, Friebel T, Spangler E, Jalloh M, MacBride S, et al. Clinical characteristics of prostate cancer in African Americans, American whites and Senegalese men. Urology. 2003; May;61(5):987–992.
Escobedo LG, Rivas SD, Holmes MD. Prostate cancer mortality in Connecticut, Iowa and New Mexico African American men. Cancer Detect.Prev. 2004;28(5):375–380.
Howe HL, Wu X, Ries LA, Cokkinides V, Ahmed F, Jemal A, et al. Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer. 2006; Oct 15;107(8):1711–1742.
Sitas F. Histologically diagnosed cancers in South Africa, 1988. S.Afr.Med.J. 1994; Jun;84(6):344–348.
Kehinde EO. The geography of prostate cancer and its treatment in Africa. Cancer Surv. 1995;23:281–286.
Osegbe DN. Prostate cancer in Nigerians: Facts and nonfacts. J.Urol. 1997; Apr;157(4):1340–1343.
Stopforth HB, Heyns CF, Allen FJ. Profile of prostate cancer in the Western Cape Province, South Africa. Afr.J.Urol. 1998;4(2):56–61.
Sitas F, Isaacson M. Histologically diagnosed cancer in South Africa, 1987. S.Afr.Med.J. 1992; Jun 6;81(11):565–568.
Quartey JKM. Carcinoma of prostate: Where do we stand in tropical Africa? Afr.J.Urol. 1994;1:72–76.
Angwafo FF, Yomi J, Mbakop A. Is cancer of the prostate rare in tropical (black) Africa? Case series from the Centre Hospitalier et Universitaire and the Hospital General de Yaounde from 1986 to 1990. Bull.Cancer Radiother. 1994;81(2):155–159.
Bassett MT, Chokunonga E, Mauchaza B, Levy L, Ferlay J, Parkin DM. Cancer in the African population of Harare, Zimbabwe, 1990–1992. Int.J.Cancer. 1995; Sep 27;63(1):29–36.
Koulibaly M, Kabba IS, Cisse A, Diallo SB, Diallo MB, Keita N, et al. Cancer incidence in Conakry, Guinea: First results from the Cancer Registry 1992–1995. Int.J.Cancer. 1997; Jan 6;70(1):39–45.
Powell IJ. Prostate cancer in the African American: Is this a different disease? Semin.Urol.Oncol. 1998; Nov;16(4):221–226.
Angwafo FF. Migration and prostate cancer: An international perspective. J.Natl.Med.Assoc. 1998; Nov;90(11 Suppl):S720–S723.
Ogunbiyi JO, Shittu OB. Increased incidence of prostate cancer in Nigerians. J.Natl.Med.Assoc. 1999; Mar;91(3):159–164.
Echimane AK, Ahnoux AA, Adoubi I, Hien S, M’Bra K, D’Horpock A, et al. Cancer incidence in Abidjan, Ivory Coast: First results from the cancer registry, 1995–1997. Cancer. 2000; Aug 1;89(3):653–663.
Wabinga HR, Parkin DM, Wabwire Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997. Br.J.Cancer. 2000; May;82(9):1585–1592.
Banda LT, Parkin DM, Dzamalala CP, Liomba NG. Cancer incidence in Blantyre, Malawi 1994–1998. Trop. Med.Int.Health. 2001; Apr;6(4):296–304.
Heyns CF, Naude AM, Visser AJ, Marais DC, Stopforth HB, Nyarko JK, et al. Early diagnosis of prostate cancer in the Western Cape. S.Afr.Med.J. 2001; Aug;91(8):679–684.
Ekwere PD, Egbe SN. The changing pattern of prostate cancer in Nigerians: Current status in the southeastern states. J.Natl.Med.Assoc. 2002; Jul;94(7):619–627.
Angwafo FF, 3rd, Zaher A, Befidi Mengue R, Wonkam A, Takougang I, Powell I, et al. High-grade intra-epithelial neoplasia and prostate cancer in Dibombari, Cameroon. Prostate Cancer.Prostatic Dis. 2003;6(1):34–38.
Glover FE,Jr, Coffey DS, Douglas LL, Cadogan M, Russell H, Tulloch T, et al. The epidemiology of prostate cancer in Jamaica. J.Urol. 1998; Jun;159(6):1984,6; discussion 1986–7.
Antonopoulos IM, Pompeo ACL, El Hayek OR, Sarkis Á S, Alfer WJ,Jr, Arap S. Results of prostate cancer screening in non-symptomatic men. Braz.J.Urol. 2001;27(3):227–234.
Ghafoor A, Jemal A, Cokkinides V, Cardinez C, Murray T, Samuels A, et al. Cancer statistics for African Americans. CA Cancer.J.Clin. 2002; Nov–Dec;52(6):326–341.
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer.J.Clin. 2005; Jan–Feb;55(1):10–30. Erratum in: CA Cancer.J.Clin. 2005; 55 (4):259.
Powell IJ, Heilbrun LK, Sakr W, Grignon D, Montie J, Novallo M, et al. The predictive value of race as a clinical prognostic factor among patients with clinically localized prostate cancer: A multivariate analysis of positive surgical margins. Urology. 1997; May;49(5):726–731.
Underwood W, 3rd, Wei J, Rubin MA, Montie JE, Resh J, Sanda MG. Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity. Urol.Oncol. 2004; Jan–Feb;22(1):20–24.
Moul JW, Douglas TH, McCarthy WF, McLeod DG. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J.Urol. 1996; May;155(5):1667–1673.
Sohayda CJ, Kupelian PA, Altsman KA, Klein EA. Race as an independent predictor of outcome after treatment for localized prostate cancer. J.Urol. 1999; Oct;162(4):1331–1336.
Paquette EL, Connelly RR, Sesterhenn IA, Zhang W, Sun L, Paquette LR, et al. Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: Implications for screening a high-risk group for prostate carcinoma. Cancer. 2001; Nov 15;92(10):2673–2679.
Kang JS, Maygarden SJ, Mohler JL, Pruthi RS. Comparison of clinical and pathological features in African-American and Caucasian patients with localized prostate cancer. BJU Int. 2004; Jun;93(9):1207–1210.
Angwafo FF, III, Sosso MA, Edzoa T. Diagnosis of carcinoma of the prostate in Yaounde: The importance of prostatic biopsy. Afr.J.Urol. 1995;1(3):197–202.
Liff JM, Chow WH, Greenberg RS. Rural-urban differences in stage at diagnosis. Possible relationship to cancer screening. Cancer. 1991; Mar 1;67(5):1454–1459.
Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS, Carroll PR. Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J.Urol. 2002; Dec;168(6):2510–2515.
Dawam D, Rafindadi AH, Kalayi GD. Benign prostatic hyperplasia and prostate carcinoma in native Africans. BJU Int. 2000; Jun;85(9):1074–1077.
Berger AD, Satagopan J, Lee P, Taneja SS, Osman I. Differences in clinicopathologic features of prostate cancer between black and white patients treated in the 1990s and 2000s. Urology. 2006; Jan;67(1):120–124.
Vijayakumar S, Winter K, Sause W, Gallagher MJ, Michalski J, Roach M, et al. Prostate-specific antigen levels are higher in African-American than in white patients in a multicenter registration study: Results of RTOG 94-12. Int.J.Radiat.Oncol.Biol.Phys. 1998; Jan 1;40(1):17–25.
Fowler JE,Jr, Bigler SA, Kilambi NK, Land SA. Relationships between prostate-specific antigen and prostate volume in black and white men with benign prostate biopsies. Urology. 1999; Jun;53(6):1175–1178.
Smith DS, Bullock AD, Catalona WJ. Racial differences in operating characteristics of prostate cancer screening tests. J.Urol. 1997; Nov;158(5):1861,5; discussion 1865–6.
Heyns CF, Mathee S, Isaacs A, Kharwa A, De Beer PM, Pretorius MA. Problems with prostate specific antigen screening for prostate cancer in the primary healthcare setting in South Africa. BJU Int. 2003; Jun;91(9):785–788.
Ukoli F, Osime U, Akereyeni F, Okunzuwa O, Kittles R, Adams Campbell L. Prevalence of elevated serum prostate-specific antigen in rural Nigeria. Int.J.Urol. 2003; Jun;10(6):315–322.
Gornick ME, Eggers PW, Reilly TW, Mentnech RM, Fitterman LK, Kucken LE, et al. Effects of race and income on mortality and use of services among Medicare beneficiaries. N.Engl.J.Med. 1996; Sep 12;335(11):791–799.
Schapira MM, McAuliffe TL, Nattinger AB. Treatment of localized prostate cancer in African-American compared with Caucasian men. Less use of aggressive therapy for comparable disease. Med.Care. 1995; Nov;33(11):1079–1988.
Orakwe JC. Endocrine treatment of urinary retention secondary to carcinoma of the prostate in Nigeria. Afr.J.Urol. 1997;3(1):32–37.
Grulich AE, Swerdlow AJ, Head J, Marmot MG. Cancer mortality in African and Caribbean migrants to England and Wales. Br.J.Cancer. 1992; Nov;66(5):905–911.
Peters N, Armstrong K. Racial differences in prostate cancer treatment outcomes: A systematic review. Cancer Nurs. 2005; Mar–Apr;28(2):108–118.
Tewari A, Horninger W, Badani KK, Hasan M, Coon S, Crawford ED, et al. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 2005; Jul;96(1):29–33.
Tewari A, Horninger W, Pelzer AE, Demers R, Crawford ED, Gamito EJ, et al. Factors contributing to the racial differences in prostate cancer mortality. BJU Int. 2005; Dec;96(9):1247–1252.
Odedina FT, Ogunbiyi JO, Ukoli FA. Roots of prostate cancer in African-American men. J.Natl.Med.Assoc. 2006; Apr;98(4):539–543.
Mohler JL, Gaston KE, Moore DT, Schell MJ, Cohen BL, Weaver C, et al. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J.Urol. 2004; Jun;171(6 Pt 1):2277–2280.
Gaston KE, Kim D, Singh S, Ford OH, 3rd, Mohler JL. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J.Urol. 2003; Sep;170(3):990–993.
Hayes RB, Ziegler RG, Gridley G, Swanson C, Greenberg RS, Swanson GM, et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol.Biomarkers Prev. 1999; Jan;8(1):25–34.
Wahnefried W, Schildkraut JM, Aldrich TE. Prostate cancer: Demographic and behavioral correlates of stage at diagnosis among blacks and whites in North Carolina. Urology. 1999; Jun;53(6):1194–1199.
McWhorter WP, Schatzkin AG, Horm JW, Brown CC. Contribution of socioeconomic status to black/white differences in cancer incidence. Cancer. 1989; Mar 1;63(5):982–987.
Howard J, Hankey BF, Greenberg RS, Austin DF, Correa P, Chen VW, et al. A collaborative study of differences in the survival rates of black patients and white patients with cancer. Cancer. 1992; May 1;69(9):2349–2360
CrossRef PubMed Copyright information
© PAUSA and Springer Verlag France 2008